These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 15305835)
1. [Physiological and pharmacological aspects of erythropoietins]. Malonne H J Pharm Belg; 2004; 59(2):41-8. PubMed ID: 15305835 [No Abstract] [Full Text] [Related]
2. Erythropoietin as a neuroprotective agent. Bell SG Neonatal Netw; 2011; 30(2):135-9. PubMed ID: 21402522 [No Abstract] [Full Text] [Related]
3. Erythropoietin: from molecular biology to clinical use. Lacombe C Eur Cytokine Netw; 1997 Sep; 8(3):308-10. PubMed ID: 9346370 [No Abstract] [Full Text] [Related]
4. [Erythropoietin in the treatment of heart failure and ischemia]. Lewartowski B Kardiol Pol; 2007 Feb; 65(2):192-7. PubMed ID: 17366366 [No Abstract] [Full Text] [Related]
5. [Erythropoietin: indications and measurement]. Klein E; Georges A; Brossaud J; Bosredon Kd; Bordenave L; Corcuff JB Ann Biol Clin (Paris); 2009; 67(5):505-15. PubMed ID: 19789122 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of recombinant erythropoietins: is there unity of international units? Jelkmann W Nephrol Dial Transplant; 2009 May; 24(5):1366-8. PubMed ID: 19225013 [No Abstract] [Full Text] [Related]
8. Medicine. A boost for translational neuroscience. Ehrenreich H Science; 2004 Jul; 305(5681):184-5. PubMed ID: 15247460 [No Abstract] [Full Text] [Related]
9. [A human recombinant erythropoietin produced in human lymphoblastoid cells]. Bounemra-Ben Ghanem A; Cherif W; Lambin P; Jenhani F; Boukef K J Pharm Belg; 1997; 52(5):177-80. PubMed ID: 9432525 [TBL] [Abstract][Full Text] [Related]
10. Recombinant human erythropoietin in the treatment of nonrenal anemia. Heuser M; Ganser A Ann Hematol; 2006 Feb; 85(2):69-78. PubMed ID: 16078035 [TBL] [Abstract][Full Text] [Related]
11. [Anaemia, cardiac failure and erythropoietin]. Cohen Solal A; Beauvais F Arch Mal Coeur Vaiss; 2005 Oct; 98(10):997-1001. PubMed ID: 16294546 [TBL] [Abstract][Full Text] [Related]
12. Recombinant human erythropoietin: has treatment reached its full potential? Fishbane S Semin Dial; 2006; 19(1):1-4. PubMed ID: 16423172 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of disease: erythropoietin--an old hormone with a new mission? Fliser D; Bahlmann FH; deGroot K; Haller H Nat Clin Pract Cardiovasc Med; 2006 Oct; 3(10):563-72. PubMed ID: 16990842 [TBL] [Abstract][Full Text] [Related]
14. The use of erythropoietin to increase red cell mass. Goodnough LT Can J Anaesth; 2003; 50(6 Suppl):S10-8. PubMed ID: 14629048 [No Abstract] [Full Text] [Related]
15. Beyond anemia: the clinical impact of the physiologic effects of erythropoietin. Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB Semin Dial; 2008; 21(5):447-54. PubMed ID: 18573136 [TBL] [Abstract][Full Text] [Related]
16. Erythropoietin and treatment of non-anemic conditions--cardiovascular protection. Fliser D; Haller H Semin Hematol; 2007 Jul; 44(3):212-7. PubMed ID: 17631185 [TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic skin ulcers in individuals with anemia of chronic disease using recombinant human erythropoietin (EPO): a review of four cases. Keast DH; Fraser C Ostomy Wound Manage; 2004 Oct; 50(10):64-70. PubMed ID: 15509883 [TBL] [Abstract][Full Text] [Related]
18. Recombinant human erythropoietins, biosimilars and immunogenicity. Schellekens H J Nephrol; 2008; 21(4):497-502. PubMed ID: 18651538 [TBL] [Abstract][Full Text] [Related]
19. [Erythropoietin: current aspects]. Espinós D An R Acad Nac Med (Madr); 1993; 110(1):19-36; discussion 37-8. PubMed ID: 8238819 [No Abstract] [Full Text] [Related]
20. To give or not to give recombinant EPO to anemia endangered cancer patients. Sulkowska M; Wincewicz A; Chabowska A; Kanczuga-Koda L; Szymanska M; Koda M; Witkowska E; Sulkowski S Prague Med Rep; 2006; 107(3):281-9. PubMed ID: 17385400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]